WallStSmart

Intelligent Bio Solutions Inc. (INBS)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 890534% more annual revenue ($37.54B vs $4.22M). MDT leads profitability with a 13.9% profit margin vs -294.9%. MDT earns a higher WallStSmart Score of 68/100 (B-).

INBS

Hold

36

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 4.7Quality: 5.0
Piotroski: 4/9Altman Z: -11.18

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INBSOvervalued (-9.6%)

Margin of Safety

-9.6%

Fair Value

$4.79

Current Price

$2.05

$2.74 premium

UndervaluedFair: $4.79Overvalued
MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$93.80

$0.63 discount

UndervaluedFair: $94.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INBS2 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
35.8%10/10

Revenue surging 35.8% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

INBS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.48M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-170.2%2/10

ROE of -170.2% — below average capital efficiency

Free Cash FlowQuality
$-3.18M2/10

Negative free cash flow — burning cash

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth. Revenue growth of 35.8% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

INBS profiles as a hypergrowth stock while MDT is a value play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.21 — expect wider price swings.

INBS is growing revenue faster at 35.8% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (68/100 vs 36/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a pioneering biotechnology company focused on delivering cutting-edge diagnostic solutions and biomarker-driven technologies, specifically designed for drug abuse testing and monitoring. Utilizing advanced scientific methodologies, INBS offers rapid and precise testing options that enhance clinical decision-making processes and improve patient outcomes. In a healthcare landscape increasingly reliant on innovative diagnostic tools, INBS is well-positioned to make substantial contributions to this evolving field, reinforcing its dedication to advancing healthcare quality and operational effectiveness.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?